Dr. Yi Chen

H.C. Wainwright & Co.

Recent Articles

Second Trial of New Eczema Drug To Commence in Q4/22 09/17/2022

The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Several Trials of Co.'s Fluid Pump To Read Out This Year 09/14/2022

Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report.


Recent Quotes

"INO's Zika virus vaccine success further validates the SynCon platform; we reiterate our Buy rating."

— Dr. Yi Chen, H.C. Wainwright & Co. (2/18/16)
more >

"The FDA cleared the clinical trial of INO's MERS vaccine, GLS-5300."

— Dr. Yi Chen, H.C. Wainwright & Co. (11/20/15)
more >

"INO's VGX-3100 could present a safe and non-surgical therapeutic option for CIN2/3."

— Dr. Yi Chen, H.C. Wainwright & Co. (9/22/15)
more >

"INO's cash balance should provide a runway to the end of 2018."

— Dr. Yi Chen, H.C. Wainwright & Co. (8/11/15)
more >

"INO announced a collaboration with the EORTC to evaluate INO-3112 for cervical cancer."

— Dr. Yi Chen, H.C. Wainwright & Co. (7/24/15)
more >

"INO initiated a Phase 1 trial to evaluate INO-4212 for Ebola."

— Dr. Yi Chen, H.C. Wainwright & Co. (5/13/15)
more >

"INO initiated a Phase 1 trial in chronic hepatitis B patients."

— Dr. Yi Chen, H.C. Wainwright & Co. (4/22/15)
more >

"We view DARPA's grant as a validation of INO's technology platform."

— Dr. Yi Chen, H.C. Wainwright & Co. (4/9/15)
more >



Due to permission requirements, not all quotes are shown.